This study investigated whether chemotherapy plus bevacizumab (Avastin) before and after or after surgery improves the survival of patients with colorectal cancer (CRC) and operable liver metastasis (LM; cancer spread to the liver). Researchers suggested that chemotherapy and bevacizumab before and after surgery improved the overall survival of these patients.

This study investigated if vitamin D supplementation improves colorectal cancer (CRC) survival outcomes. Researchers suggested that vitamin D supplementation is associated with improved survival in CRC.

This study investigated Immunoscore (IMS) as a prognostic tool in patients with stage 3 colon cancer. Researchers suggested that a high IMS is associated with prolonged survival in these patients.

This study compared the effectiveness of three different treatments for metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that fruquintinib (Elunate) was associated with the best treatment outcomes.

This analysis was carried out to look at including regorafenib (Stivarga) in second-line therapy for patients with metastatic colorectal cancer (mCRC). The authors found that regorafenib in combination with chemotherapy might be an alternative to standard second-line treatment options for these patients.

This study compared the survival outcomes of different chemotherapy treatments in patients with inoperable advanced colorectal cancer (CRC). Researchers suggested that FOLFOXIRI plus bevacizumab (Avastin) significantly improved the survival of these patients.

This study investigated the effects of bevacizumab (Avastin) combined with mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) treatment in RAS-positive advanced colorectal cancer (CRC). Researchers suggested that this treatment improved the treatment and survival outcomes of patients with CRC and liver metastasis (spread to the liver).

This study investigated the impact of hepatic artery infusion (HAI) after advanced colorectal cancer surgery in patients with liver metastasis. Researchers suggested that HAI is associated with improved outcomes in these patients regardless of KRAS mutation status.

This study investigated the differences in following the guidelines for advanced rectal cancer treatments. Researchers suggested chemotherapy after the complete removal of rectal cancer improves survival.

This phase 2 trial is examining the effectiveness of TAS-102 (Lonsurf) plus oxaliplatin (Eloxatin) in the treatment of metastatic (spread to other parts of the body) colorectal cancer. The main outcome to be measured will be the overall response to the treatment rate. This study is being conducted in New Jersey, US.